HURA — TuHURA Biosciences Share News
0.000.00%
Last trade - 00:00- $131.28m
- $134.16m
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.
Brief: Tuhura Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides A Corporate Update
Brief: Tuhura Biosciences Received FDA Orphan Drug Designation For Ifx-2.0
Brief: Tuhura Biosciences Releases Kintara CVR After Safety Milestone
TuHURA Biosciences plunges after $15.6 million direct stock deal
Brief: TuHURA Biosciences Signs ATM Deal With H.C. Wainwright To Sell Stock Worth Up To $50 Million – SEC Filing
Brief: Tuhura Biosciences Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Brief: Tuhura Biosciences Initiates Its Phase 3 Accelerated Approval Trial Of IFx-2.0
Brief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: FDA Removes Partial Clinical Hold On TuHURA Biosciences' Phase 3 Accelerated Approval Trial For IFx-2.0 In Advanced Or Metastatic Merkel Cell Carcinoma
Brief: Tuhura Biosciences Secures $12.5 Mln In Private Offering
TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: TuHURA Biosciences Reports First Quarter 2025 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President
TuHURA Biosciences Inc expected to post a loss of 13 cents a share - Earnings Preview